ex vivo HBB-transduced autologous hematopoietic stem cell therapy (Allife Medical Science and Technology)

N/A

报告时间: 2025/02/01 20:00:06

基本信息

药物名称ex vivo HBB-transduced autologous hematopoietic stem cell therapy (Allife Medical Science and Technology)

药物别称HBB gene-tranduced iHSCs (Allife Medical Science and Technology)ex vivo CRISPR/Cas9/HBB stem cell-based gene therapy (Allife Medical Science and Technology)Ex Vivo HBB-Edited Hematopoietic Stem Cell Therapy (Allife Medical Science and Technology)ex vivo HBB-transduced autologous hematopoietic stem cell therapy (Beijing Allife Medicine Technology)

药物类型细胞与基因疗法 > 细胞疗法 > 干细胞疗法 > 造血干细胞疗法

作用机制血红蛋白β链刺激剂

靶点血红蛋白β链

治疗领域 / 适应症β-地中海贫血

全球批准适应症N/A

中国批准适应症N/A

首批国家/区域N/A

首批日期N/A

国家/区域英国

是否复方否

全球最高研发状态无进展 (临床前)

中国最高研发状态N/A

原研公司Epsilon Molecular Engineering Inc

注册分类N/A

研发信息

活跃公司N/A

非活跃公司Epsilon Molecular Engineering Inc

活跃适应症N/A

非活跃适应症β-地中海贫血

其他信息

ATC代码N/A